Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Nephrology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nephropathy Clinical Trials

A listing of Nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (29) clinical trials

Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy

The objective of the study is to evaluate the effect of the administration of green tea extract on soluble RAGE and renal damage in patients with Type 2 Diabetes Mellitus, by means of a clinical trial, double blind, with randomization and placebo control group. In male and female population, with ...


Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

MVC is a CCR5 inhibitor that may have a positive role in modulating the immune response following transplantation. The purpose of this study is to evaluate the safety and tolerability of MVC in HIV-infected adults in need of a kidney transplant. The study will also evaluate whether using both immunosuppressant ...


A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)


Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with DKD who are already taking irbesartan by: monitoring symptoms that participants may experience while on the study, measuring levels of protein in participant's urine and kidney function during the course of the study, ...


Efficacy of ACE Inhibitors MRAs and ACE Inhibitor/ MRA Combination

Diabetic nephropathy (DN) is the most common cause renal failure in Western countries, responsible for 45% of patients on renal replacement therapy.Diabetic nephropathy was characterized in the early stage by increased albumin excretion in urine, known as microalbuminuria. (DN) results from interactions between different pathological factors that include hyperglycemia, increased ...


A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx an Antisense Inhibitor of Complement Factor B in Adult Participants With Primary IgA Nephropathy

This is a Phase 2, single arm open-label clinical study in up to 10 participants that will consist of screening period (which may include a titration of maximum dose/maximally tolerated dose of angiotensin converting enzyme (ACE) and/or angiotensin II receptor blocker (ARB)), a 24-week treatment period and a 12-week post-treatment ...


A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are ...


A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Seventy-one patients with CAPS will be recruited. After signing the informed consent, they will be administrated with tranilast (For juvenile patients, 5mg/kg.d with a maximum dose of 0.3g per day; For adult patients, the dose is 0.1g each time, three times a day). These patients will be followed up for ...


Oral LAT8881 in Neuropathic Pain

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain. After a one week baseline period, subjects entered into the study will be randomised to receive Investigational Medicinal Product (IMP) (LAT8881 or placebo) twice daily for four weeks. ...